Skip to main content
SpringerLink
Log in

Re-evaluating PARP1 inhibitor in cancer

  • Correspondence
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Model explaining the differences in PARP1 inhibitor effectiveness between inhibitor-sensitive and inhibitor-insensitive cancer cells.

References

  1. Guha, M. Nat. Biotechnol. 29, 373–374 (2011).

    Article  CAS  Google Scholar 

  2. D'Amours, D., Desnoyers, S., D'Silva, I. & Poirier, G.G. Biochem. J. 342, 249–268 (1999).

    Article  CAS  Google Scholar 

  3. Menisser-de Murcia, J., Mark, M., Wendling, O., Wynshaw-Boris, A. & de Murcia, G. Mol. Cell. Biol. 21, 1828–1832 (2001).

    Article  CAS  Google Scholar 

  4. Gottipati, P. et al. Cancer Res. 70, 5389–5398 (2010).

    Article  CAS  Google Scholar 

  5. Mendoza-Alvarez, H. & Alvarez-Gonzalez, R. J. Biol. Chem. 268, 22575–22580 (1993).

    CAS  PubMed  Google Scholar 

  6. Krishnakumar, R. et al. Science 319, 819–821 (2008).

    Article  CAS  Google Scholar 

  7. Tulin, A., Stewart, D. & Spradling, A.C. Genes Dev. 16, 2108–2119 (2002).

    Article  CAS  Google Scholar 

  8. Beneke, S. et al. Nucleic Acids Res. 36, 6309–6317 (2008).

    Article  CAS  Google Scholar 

  9. Salvati, E. et al. Oncogene 29, 6280–6293 (2010).

    Article  CAS  Google Scholar 

  10. Aubin, R.J. et al. EMBO J. 2, 1685–1693 (1983).

    Article  CAS  Google Scholar 

  11. Tulin, A. & Spradling, A. Science 299, 560–562 (2003).

    Article  CAS  Google Scholar 

  12. Kim, M.Y., Mauro, S., Gevry, N., Lis, J.T. & Kraus, W.L. Cell 119, 803–814 (2004).

    Article  CAS  Google Scholar 

  13. Oliver, F.J. et al. EMBO J. 18, 4446–4454 (1999).

    Article  CAS  Google Scholar 

  14. Dajee, M. et al. Nature 421, 639–643 (2003).

    Article  CAS  Google Scholar 

  15. Petesch, S.J. & Lis, J.T. Cell 134, 74–84 (2008).

    Article  CAS  Google Scholar 

  16. Leu, J.I., Pimkina, J., Frank, A., Murphy, M.E. & George, D.L. Mol. Cell 36, 15–27 (2009).

    Article  CAS  Google Scholar 

  17. Bryant, H.E. et al. Nature 434, 913–917 (2005).

    Article  CAS  Google Scholar 

  18. Tulin, A., Naumova, N.M., Menon, A.K. & Spradling, A.C. Genetics 172, 363–371 (2006).

    Article  CAS  Google Scholar 

  19. Kotova, E., Jarnik, M. & Tulin, A.V. PLoS Genet. 5, e1000387 (2009).

    Article  Google Scholar 

  20. Pinnola, A.D., Naumova, N., Shah, M. & Tulin, A.V. J. Biol. Chem. 282, 32511–32519 (2007).

    Article  CAS  Google Scholar 

  21. Kotova, E. et al. Proc. Natl. Acad. Sci. USA 108, 6205–6210 (2011).

    Article  CAS  Google Scholar 

  22. Kotova, E., Pinnola, A.D. & Tulin, A.V. Methods Mol. Biol. 780, 491–516 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

    Alexei Tulin

Authors
  1. Alexei Tulin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexei Tulin.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tulin, A. Re-evaluating PARP1 inhibitor in cancer. Nat Biotechnol 29, 1078–1079 (2011). https://doi.org/10.1038/nbt.2058

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2058

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation